Open in Screener

TNGX

Tango Therapeutics Inc

Aug 15 • 04:00PM ET

6.77

Dollar change -0.15
Percentage change -2.17	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BEAM KRYS PLRX EDIT SGMO FDMT AFMD VCNX

| Held by: IWM VTI VXF IWN IBB SCHA VTWO IWC ITOT VHT

Index	RUT	P/E	-	EPS (ttm)	-1.33	Insider Own	44.42%	Shs Outstand	110.87M	Perf Week	2.42%
Market Cap	753.23M	Forward P/E	-	EPS next Y	-1.39	Insider Trans	0.00%	Shs Float	61.84M	Perf Month	-1.31%
Enterprise Value	607.03M	PEG	-	EPS next Q	-0.07	Inst Own	72.33%	Short Float	36.35%	Perf Quarter	345.39%
Income	-145.57M	P/S	31.00	EPS this Y	6.75%	Inst Trans	10.56%	Short Ratio	6.95	Perf Half Y	169.72%
Sales	24.30M	P/B	5.56	EPS next Y	-25.34%	ROA	-47.01%	Short Interest	22.48M	Perf YTD	119.09%
Book/sh	1.22	P/C	4.16	EPS next 5Y	-7.26%	ROE	-76.09%	52W High	12.02 -43.65%	Perf Year	-25.19%
Cash/sh	1.63	P/FCF	-	EPS past 3/5Y	-8.36% 7.47%	ROIC	-86.94%	52W Low	1.03 557.28%	Perf 3Y	36.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.33% 53.11%	Gross Margin	89.76%	Volatility	5.92% 7.82%	Perf 5Y	-
Dividend TTM	-	EV/Sales	24.98	EPS Y/Y TTM	-17.32%	Oper. Margin	-647.34%	ATR (14)	0.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.75	Sales Y/Y TTM	-42.84%	Profit Margin	-599.11%	RSI (14)	58.43	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	4.75	EPS Q/Q	-49.00%	SMA20	1.92%	Beta	1.65	Target Price	10.86
Payout	-	Debt/Eq	0.26	Sales Q/Q	-83.99%	SMA50	15.94%	Rel Volume	0.31	Prev Close	6.92
Employees	155	LT Debt/Eq	0.24	Earnings	Aug 05 BMO	SMA200	99.50%	Avg Volume	3.24M	Price	6.77
IPO	Sep 03, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.80% -52.55%	Trades		Volume	1,017,492	Change	-2.17%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-17-24	Initiated	Jefferies	Buy	$19
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight	$18
Dec-08-23	Initiated	B. Riley Securities	Buy	$16
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy	$10
Sep-20-21	Initiated	SVB Leerink	Outperform	$25

Aug-05-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Aug-04-25 09:53AM	Tango Therapeutics Inc (TNGX) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-31-25 07:40PM	IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates (Zacks) +8.11%
Jul-30-25 10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
09:55AM	Loading…
09:55AM	Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade (Zacks)
Jul-29-25 10:00AM	Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-22-25 07:00AM	Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 (GlobeNewswire)
Jul-14-25 09:55AM	Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? (Zacks)
Jun-30-25 05:47AM	Tango doses first subject in MTAP-deleted and RAS mutant cancer trial (Clinical Trials Arena)
Jun-27-25 07:00AM	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer (GlobeNewswire)
Jun-23-25 09:07AM	Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? (Zacks)
May-27-25 07:00AM	Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire) +11.41%
May-21-25 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors (GlobeNewswire) -8.70%
May-12-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +14.91%
07:00AM	Loading…
07:00AM	Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
May-09-25 09:45AM	Tango Therapeutics Inc (TNGX) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-06-25 08:20AM	Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -11.27%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -5.96%
May-01-25 07:00AM	Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire)
Apr-09-25 05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire) +16.53%
Mar-25-25 04:30PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -5.75% -6.10%
Feb-27-25 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -6.44%
Feb-20-25 07:30AM	Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences (GlobeNewswire)
Jan-30-25 07:00AM	Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference (GlobeNewswire)
Dec-03-24 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.14%
Nov-27-24 07:00AM	Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +6.25%
Nov-23-24 10:26AM	Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-06-24 07:05AM	Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights (Business Wire) -37.45%
07:00AM	Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program (Business Wire)
07:00AM	Loading…
Aug-28-24 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Aug-18-24 09:03AM	Jefferies Predicts up to 270% Rally for These 2 Strong Buy Stocks (TipRanks)
Aug-07-24 07:00AM	Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
Jun-14-24 05:10AM	Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? (Zacks) +6.44%
Jun-05-24 07:00AM	Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-23-24 09:18AM	Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program (PR Newswire)
07:00AM	Tango Therapeutics Announces Discontinuation of TNG348 Program (Business Wire)
May-08-24 01:53PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
May-07-24 10:00AM	Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-01-24 04:48PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-20-24 05:31AM	Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
Mar-18-24 02:52PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.09%
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-06-24 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Mar-05-24 04:47PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
Feb-07-24 08:55AM	Pancreatic Cancer Treatments Poised for Major Advances in 2024 (PR Newswire)
Jan-31-24 07:00AM	Tango Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-05-24 04:05PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-24 02:47AM	Medivirs licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study (PR Newswire)
Jan-03-24 07:00AM	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers (GlobeNewswire)
Nov-13-23 07:00AM	Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting (GlobeNewswire) -9.45%
Nov-08-23 03:12PM	Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-07-23 07:00AM	Tango Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-10-23 11:28AM	Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why (Zacks)
Oct-09-23 08:50AM	What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing' (Zacks) -13.27%
Sep-18-23 07:00AM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.88%
Sep-06-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers (GlobeNewswire)
Sep-05-23 07:00AM	Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-29-23 05:08PM	Tango Therapeutics Announces Updates to Its Board of Directors (GlobeNewswire) -7.51%
Aug-28-23 07:00AM	Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer (GlobeNewswire)
Aug-10-23 07:00AM	Tango Therapeutics Announces $80 million Private Placement Financing (GlobeNewswire) -16.26%
Aug-07-23 07:00AM	Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-24-23 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers (GlobeNewswire)
Jul-10-23 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors (GlobeNewswire)
Jun-01-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-23 07:00AM	Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire) +6.40%
Apr-18-23 04:30PM	Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting (GlobeNewswire) -11.67%
Apr-03-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers (GlobeNewswire) +10.38%
Mar-27-23 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -9.35%
Mar-14-23 08:11PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting (GlobeNewswire)
Mar-10-23 10:15PM	Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank (GlobeNewswire) -13.33% +6.45%
Mar-06-23 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-28-23 07:00AM	Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development (GlobeNewswire) +6.09%
Feb-02-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-25-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates (GlobeNewswire)
Dec-15-22 07:00AM	HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors (GlobeNewswire)
Nov-10-22 07:00AM	Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -5.27%
Nov-07-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-19-22 07:00AM	Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-05-22 08:10AM	Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting (GlobeNewswire)
Sep-06-22 07:00AM	Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) -12.62%
Aug-13-22 08:27AM	The Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts (Simply Wall St.)
Aug-10-22 07:00AM	Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +22.41%
Aug-02-22 07:00AM	Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire) +6.30%
Jun-27-22 07:00AM	Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes (GlobeNewswire)
Jun-20-22 07:26AM	We Think Tango Therapeutics (NASDAQ:TNGX) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-08-22 07:00AM	Tango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
May-11-22 07:00AM	Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -7.57%
May-09-22 07:00AM	Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022 (GlobeNewswire) -12.62%
Apr-19-22 07:22AM	Shareholders in Tango Therapeutics (NASDAQ:TNGX) are in the red if they invested a year ago (Simply Wall St.)
Mar-28-22 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-08-22 04:57PM	Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting (GlobeNewswire)
Mar-03-22 09:41AM	Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress (GlobeNewswire) -7.42%
Feb-28-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barry Douglas	General Counsel	Feb 04 '25	Sale	2.99	2,774	8,289	68,570	Feb 06 08:21 PM
Barry Douglas	General Counsel	Feb 05 '25	Sale	3.16	2,556	8,081	66,014	Feb 06 08:21 PM
Beckman Daniella	Chief Financial Officer	Feb 04 '25	Sale	2.99	4,284	12,801	154,232	Feb 06 08:10 PM
Beckman Daniella	Chief Financial Officer	Feb 05 '25	Sale	3.16	3,948	12,481	150,284	Feb 06 08:10 PM
Crystal Adam	See Remarks	Feb 04 '25	Sale	2.99	7,432	22,207	165,061	Feb 06 08:08 PM
Crystal Adam	See Remarks	Feb 05 '25	Sale	3.16	6,851	21,659	158,210	Feb 06 08:08 PM
Weber Barbara	Chief Executive Officer	Feb 04 '25	Sale	2.99	9,778	29,217	1,631,264	Feb 06 08:02 PM
Weber Barbara	Chief Executive Officer	Feb 05 '25	Sale	3.16	9,013	28,494	1,622,251	Feb 06 08:02 PM
Rothenberg Mace	Director	Nov 18 '24	Buy	3.78	10,000	37,800	31,250	Nov 18 07:20 PM
Rothenberg Mace	Director	Nov 14 '24	Buy	3.62	10,000	36,200	21,250	Nov 18 07:20 PM
EcoR1 Capital, LLC	10% Owner	Nov 06 '24	Sale	3.28	1,494,558	4,896,023	11,836,178	Nov 08 07:24 PM
EcoR1 Capital, LLC	10% Owner	Nov 07 '24	Sale	2.94	1,205,442	3,539,720	10,630,736	Nov 08 07:24 PM
Boxer Capital Management, LLC		Nov 06 '24	Sale	3.14	3,080,000	9,671,200	3,610,642	Nov 07 09:30 PM
Boxer Capital Management, LLC	Member of group formerly ownin	Nov 06 '24	Proposed Sale	5.18	575,000	2,978,500		Nov 06 09:40 PM
Boxer Capital Management, LLC		Oct 25 '24	Sale	6.87	633,000	4,348,710	6,690,642	Oct 28 06:59 AM
Boxer Capital Management, LLC	Member of group owning over 10	Oct 25 '24	Proposed Sale	6.29	100,000	629,000		Oct 25 09:30 PM
Boxer Capital Management, LLC		Oct 21 '24	Sale	7.05	625,000	4,406,250	7,573,642	Oct 23 09:31 PM
Boxer Capital Management, LLC		Oct 22 '24	Sale	6.78	250,000	1,695,000	7,323,642	Oct 23 09:31 PM
Boxer Capital Management, LLC	Member of group owning over 10	Oct 22 '24	Proposed Sale	7.15	127,600	912,340		Oct 22 08:50 PM
Boxer Capital Management, LLC	Member of group owning over 10	Oct 21 '24	Proposed Sale	7.46	500,000	3,730,000		Oct 22 12:03 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 13 '24	Sale	10.53	67,400	709,756	16,859,075	Sep 17 04:48 PM
Third Rock Ventures IV, L.P.	Affiliate	Sep 13 '24	Proposed Sale	10.50	67,400	707,700		Sep 13 05:43 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 05 '24	Sale	11.56	75,000	867,135	16,926,475	Sep 09 07:19 PM
Third Rock Ventures IV, L.P.	Affiliate	Sep 05 '24	Proposed Sale	11.68	75,000	876,000		Sep 05 05:01 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 30 '24	Sale	11.60	175,000	2,029,702	17,001,475	Sep 04 08:42 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 30 '24	Proposed Sale	11.83	175,000	2,070,250		Aug 30 05:24 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 27 '24	Sale	11.55	25,000	288,665	17,176,475	Aug 29 04:40 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 27 '24	Proposed Sale	11.40	25,000	285,000		Aug 27 04:53 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 19 '24	Sale	10.09	150,000	1,513,920	17,201,475	Aug 20 05:59 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 19 '24	Proposed Sale	10.68	150,000	1,602,000		Aug 19 05:35 PM

Open in Screener

ITOS

ITeos Therapeutics Inc

Aug 15 • 04:00PM ET

10.11

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

ITOS ITeos Therapeutics Inc daily Stock Chart

Peers: MRNA AZN BMY GILD AMGN PFE JNJ REGN VRTX INCY

| Held by: VTI IWM VXF IWN IBB VTWO SCHA DFAT FESM VHT

Index	RUT	P/E	-	EPS (ttm)	-4.85	Insider Own	6.26%	Shs Outstand	44.17M	Perf Week	0.00%
Market Cap	446.92M	Forward P/E	-	EPS next Y	-1.63	Insider Trans	480.50%	Shs Float	41.44M	Perf Month	-1.46%
Enterprise Value	-63.38M	PEG	-	EPS next Q	-1.28	Inst Own	93.28%	Short Float	7.16%	Perf Quarter	26.85%
Income	-202.41M	P/S	-	EPS this Y	-8.49%	Inst Trans	26.18%	Short Ratio	1.96	Perf Half Y	39.06%
Sales	0.00M	P/B	0.90	EPS next Y	54.86%	ROA	-29.44%	Short Interest	2.97M	Perf YTD	31.64%
Book/sh	11.18	P/C	0.87	EPS next 5Y	3.89%	ROE	-34.97%	52W High	18.13 -44.24%	Perf Year	-34.39%
Cash/sh	11.66	P/FCF	-	EPS past 3/5Y	- -34.39%	ROIC	-40.69%	52W Low	4.80 110.62%	Perf 3Y	-62.68%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-53.35% -	Gross Margin	-	Volatility	0.42% 0.69%	Perf 5Y	-65.01%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-61.86%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.53	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	53.15	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.53	EPS Q/Q	-906.80%	SMA20	-0.09%	Beta	1.31	Target Price	10.30
Payout	-	Debt/Eq	0.01	Sales Q/Q	-100.00%	SMA50	-0.08%	Rel Volume	0.96	Prev Close	10.11
Employees	173	LT Debt/Eq	0.01	Earnings	Apr 28 AMC	SMA200	22.85%	Avg Volume	1.51M	Price	10.11
IPO	Jul 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.79% -100.00%	Trades		Volume	1,459,934	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$12
May-28-25	Downgrade	Wedbush	Outperform → Neutral	$12
May-14-25	Downgrade	Leerink Partners	Outperform → Market Perform	$9
May-14-25	Downgrade	H.C. Wainwright	Buy → Neutral
May-13-25	Downgrade	JP Morgan	Overweight → Neutral
Aug-13-24	Initiated	Wells Fargo	Overweight	$31
May-05-21	Initiated	H.C. Wainwright	Buy	$37
Oct-08-20	Initiated	Robert W. Baird	Outperform	$45
Aug-18-20	Initiated	Wedbush	Outperform	$45
Aug-18-20	Initiated	SVB Leerink	Outperform	$45
Aug-18-20	Initiated	Piper Sandler	Overweight	$50
Aug-18-20	Initiated	JP Morgan	Overweight	$40

Show Previous Ratings

Jul-22-25 07:35AM	Replimune drug rejected by FDA; Omega raises $647M biotech fund (BioPharma Dive)
Jul-21-25 07:29AM	iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right (GlobeNewswire)
May-30-25 12:00PM	iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know (Zacks)
May-29-25 07:59AM	iTeos to shut down following $2bn GSK-partnered TIGIT asset failure (Pharmaceutical Technology)
May-28-25 08:30AM	iTeos Therapeutics Announces Its Intention to Wind Down Operations (GlobeNewswire) +17.94%
08:10AM	Loading…
08:10AM	Cancer drugmaker iTeos to shut down (BioPharma Dive)
May-15-25 07:55AM	GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug (Zacks)
May-14-25 06:00AM	GSK and iTeos drop anti-TIGIT drug following trial failure (Clinical Trials Arena)
May-13-25 12:35PM	iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile (Benzinga) +13.44%
07:55AM	iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients (GlobeNewswire)
07:10AM	iTeos, GSK to shelve TIGIT drug after study setback (BioPharma Dive)
May-02-25 09:55AM	Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High? (Zacks)
Apr-28-25 04:30PM	iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-25-25 04:35PM	iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 (GlobeNewswire) -5.44%
Mar-13-25 09:55AM	Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet (Zacks)
07:00AM	Loading…
Mar-05-25 07:00AM	iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire) +5.99%
Jan-13-25 12:00PM	All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy (Zacks)
Jan-10-25 07:00AM	iTeos Announces 2025 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-08-25 07:00AM	iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-24 07:20AM	iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo (TipRanks)
Dec-13-24 01:25PM	Inupadenant deprioritised by iTeos in favour of pipeline TIGIT therapy (Clinical Trials Arena)
Dec-12-24 08:55AM	iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-26-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 07:00AM	iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-24-24 07:00AM	iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress (GlobeNewswire)
Oct-16-24 01:01AM	BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-30-24 01:01PM	TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-16-24 04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily) -27.54%
Sep-15-24 09:12PM	ESMO 2024: TIGIT race tightens with first look at GSK/iTeoss TIGIT in NSCLC (Pharmaceutical Technology)
Sep-14-24 08:10AM	TIGIT drug from iTeos shrinks lung tumors in trial (BioPharma Dive)
02:30AM	Loading…
02:30AM	iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients (GlobeNewswire)
Aug-28-24 04:30PM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-24 08:30AM	iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 (GlobeNewswire) +10.13%
Aug-08-24 08:20AM	ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-05-24 07:00AM	iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer (GlobeNewswire)
Jul-09-24 12:33PM	iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial (Pharmaceutical Technology)
Jul-08-24 07:00AM	iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK (GlobeNewswire)
Jun-18-24 06:33AM	iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC (Clinical Trials Arena)
Jun-17-24 09:00AM	iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer (GlobeNewswire) -6.04%
May-13-24 08:28AM	HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating (MT Newswires)
May-10-24 01:53PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +43.07%
12:21PM	Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating (MT Newswires)
09:40AM	iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump (MT Newswires)
08:26AM	iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
08:24AM	iTeos Therapeutics Announces $120 Million Registered Direct Offering (GlobeNewswire)
08:09AM	iTeos shares jump on TIGIT update; Acelyrin swaps CEOs (BioPharma Dive)
Apr-07-24 04:30PM	iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-06-24 02:51PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +7.80%
07:01AM	iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors (GlobeNewswire)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-24 04:30PM	iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.23%
Feb-26-24 06:11AM	Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength? (Zacks)
Jan-08-24 07:00AM	iTeos Announces 2024 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-03-24 07:00AM	iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 09:55AM	Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade (Zacks)
Nov-27-23 09:55AM	Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect? (Zacks) -5.44%
Nov-21-23 07:00AM	iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-13-23 09:55AM	Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-10-23 09:55AM	Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know (Zacks)
Nov-07-23 07:00AM	iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-31-23 03:01AM	Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar? (Zacks) +7.48%
Oct-16-23 01:46PM	Hedge Fund and Insider Trading News: Ken Griffin, EcoR1 Capital, Glen Point Capital, JAT Capital, Eisler Capital, Elliott Management, iTeos Therapeutics Inc (ITOS), Funko, Inc. (FNKO), and More (Insider Monkey)
04:38AM	iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar? (Zacks)
Oct-11-23 05:55PM	NCR Atleos Set to Join S&P SmallCap 600 (PR Newswire) -6.72% -6.39%
Sep-06-23 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-23 11:02AM	BOXER CAPITAL, LLC Reduces Stake in ITeos Therapeutics Inc (GuruFocus.com)
Aug-24-23 11:30AM	Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak (Zacks)
Aug-23-23 04:10PM	Why Roche's Accidental Cancer Update Boosted Several Rivals By As Much As 22% (Investor's Business Daily) +14.89%
02:00PM	Watertown biotech shares spike after accidental data publication at Roche (American City Business Journals)
09:24AM	How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30% (Investor's Business Daily)
Aug-08-23 07:00AM	iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-21-23 08:00PM	ITOS: Lowering target price to $11.00 (Argus Research)
May-13-23 08:03AM	Broker Revenue Forecasts For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Are Surging Higher (Simply Wall St.)
May-11-23 06:11AM	iTeos Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-10-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:01AM	iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
May-05-23 08:51AM	iTeos Therapeutics (NASDAQ:ITOS) shareholders have endured a 46% loss from investing in the stock a year ago (Simply Wall St.)
Apr-26-23 08:00PM	ITOS: What does Argus have to say about ITOS? (Argus Research)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Mar-21-23 06:07AM	Take Care Before Jumping Onto iTeos Therapeutics, Inc. (NASDAQ:ITOS) Even Though It's 25% Cheaper (Simply Wall St.)
Mar-17-23 06:18AM	Time To Worry? Analysts Are Downgrading Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Outlook (Simply Wall St.)
Mar-15-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-28-23 07:00AM	iTeos to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 01:51PM	The 7 Best Biotech Stocks to Buy for February 2023 (InvestorPlace)
07:00AM	iTeos to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-02-23 02:19PM	The 7 Most Undervalued Biotech Stocks to Buy in February 2023 (InvestorPlace)
Jan-09-23 07:00AM	iTeos Provides Business Updates and Clinical Development Plans for 2023 (GlobeNewswire)
Jan-03-23 07:00AM	iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.07%
Dec-07-22 08:07AM	Could The Market Be Wrong About iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Its Attractive Financial Prospects? (Simply Wall St.)
Nov-22-22 07:00AM	iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) -5.98%
Nov-10-22 07:55PM	ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates (Zacks) +11.14%
04:01PM	iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-22 05:46PM	Top Biotech Stocks for Q4 2022 (Investopedia)
Nov-02-22 10:00AM	ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-22 08:36AM	Shareholders in iTeos Therapeutics (NASDAQ:ITOS) are in the red if they invested a year ago (Simply Wall St.)
Aug-12-22 06:16AM	iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.) +7.00%
Aug-10-22 05:25PM	ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates (Zacks) -12.51%

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Detheux Michel	Chief Executive Officer	Jun 10 '25	Option Exercise	4.30	137,910	593,013	94,027	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Option Exercise	4.30	43,882	188,693	43,882	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 10 '25	Option Exercise	4.30	26,400	113,520	153,903	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Sale	10.03	43,882	440,136	0	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 10 '25	Sale	10.02	43,883	439,708	0	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Sale	10.03	8,400	84,252	135,903	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 10 '25	Sale	10.02	8,400	84,168	135,903	Jun 11 09:01 PM
Detheux Michel	Officer	Jun 10 '25	Proposed Sale	10.02	52,283	523,876		Jun 10 04:19 PM
Detheux Michel	Officer	Jun 09 '25	Proposed Sale	10.17	52,282	531,708		Jun 09 04:12 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Option Exercise	4.30	43,883	188,697	43,883	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Option Exercise	4.30	43,882	188,693	43,882	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Option Exercise	4.30	43,882	188,693	43,882	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Sale	10.21	43,882	448,035	0	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Sale	10.15	43,882	445,402	0	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Sale	10.10	43,883	443,218	0	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Sale	10.21	8,400	85,764	135,903	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Sale	10.15	8,400	85,260	135,903	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Sale	10.10	8,400	84,840	135,903	Jun 06 09:03 PM
Hallal David	Director	Jun 06 '25	Option Exercise	4.30	38,228	164,380	38,228	Jun 06 09:03 PM
Hallal David	Director	Jun 04 '25	Option Exercise	4.30	38,227	164,376	38,227	Jun 06 09:03 PM
Hallal David	Director	Jun 05 '25	Option Exercise	4.30	38,227	164,376	38,227	Jun 06 09:03 PM
Hallal David	Director	Jun 06 '25	Sale	10.24	38,228	391,455	0	Jun 06 09:03 PM
Hallal David	Director	Jun 05 '25	Sale	10.15	38,227	388,004	0	Jun 06 09:03 PM
Hallal David	Director	Jun 04 '25	Sale	10.07	38,227	384,946	0	Jun 06 09:03 PM
Detheux Michel	Officer	Jun 06 '25	Proposed Sale	10.19	52,282	532,754		Jun 06 04:11 PM
DAVID L HALLAL	Director	Jun 06 '25	Proposed Sale	10.24	38,228	391,489		Jun 06 04:09 PM
DAVID L HALLAL	Director	Jun 05 '25	Proposed Sale	10.15	38,227	388,103		Jun 05 04:27 PM
Detheux Michel	Officer	Jun 05 '25	Proposed Sale	10.22	52,282	534,322		Jun 05 04:10 PM
Detheux Michel	Officer	Jun 04 '25	Proposed Sale	10.06	52,283	525,967		Jun 04 04:03 PM
DAVID L HALLAL	Director	Jun 04 '25	Proposed Sale	10.07	38,227	384,782		Jun 04 04:03 PM
EcoR1 Capital, LLC	10% Owner	May 15 '25	Buy	8.00	3,300,000	26,400,000	10,688,978	May 16 06:52 PM
EcoR1 Capital, LLC	10% Owner	May 14 '25	Buy	7.41	1,658,978	12,285,562	7,388,978	May 16 06:52 PM
GADICKE ANSBERT	Former 10% Owner	May 13 '25	Sale	8.06	1,031,931	8,317,364	3,452,797	May 15 05:34 PM
MPM BIOVENTURES 2018, L.P.	Former 10% Owner	May 13 '25	Sale	8.06	630,191	5,079,339	2,108,594	May 15 05:33 PM
MPM BioVentures 2014, L.P.	Former 10% Owner	May 13 '25	Sale	8.06	630,191	5,079,339	2,108,594	May 15 05:32 PM
Van Hauwermeiren Timothy	Director	May 13 '25	Option Exercise	4.30	22,346	96,088	22,346	May 14 08:00 PM
Gall Matthew	Chief Financial Officer	Nov 19 '24	Buy	7.73	5,000	38,635	65,429	Nov 19 07:59 PM

TNGX

Tango Therapeutics Inc

ITOS

ITeos Therapeutics Inc

Upgrade your FINVIZ experience